Javier Cortés, MD
Advertisement
Articles by Javier Cortés, MD
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Rui Rui Zhang,Miguel Sampayo-Cordero,Juliana Carvalho-Santos,Olga Boix,Marta Beltran,Carlos Barrios,Guiseppe Curigliano,Rupert Bartsch,Anne Clair Hardy Bessard,Anna Compagnoni,Kathy Puyana Theall,Thomas Buechele,Tomer Wasserman,Javier Cortés, MD
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
ByHeather McArthur, MD, MPH,Peter A. Fasching,Rebecca Dent, MD,Javier Cortés, MD,Lajos Pusztai, MD, DPhil,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck, MD, PhD,Masato Takahashi,Seock-Ah Im,Michael Untch, MD, PhD,Marie-Ange Mouret-Reynier,Theodoros Foukakis,Marta Ferreira,Fatima Cardoso,Yu Ding,Cecilia Pinheiro,Jaime Mejia,Joyce A. O’Shaughnessy,Peter Schmid, MD
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Marina Sharifi,Kristine Rinn,Wassim McHayleh,Rinat Yerushalmi,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Bartomeu Piza Vallespir,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Eva Ciruelos,Ji-Yeon Kim,Elena López-Miranda,Elia Seguí,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Alessandro Di Sanzo,Paula Muñoz Romero,Bartomeu Piza Vallespir,Manuel Dominguez,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
ByFatima Cardoso,Joyce O’Shaughnessy, MD,Heather McArthur, MD, MPH,Peter Schmid, MD,Javier Cortés, MD,Nadia Harbeck, MD, PhD,Melinda L. Telli, MD,David W. Cescon,Peter A. Fasching,Zhimin Shao,Delphine Loirat,Yeon Hee Park,Manuel Gonzalez Fernandez,Gábor Rubovszky,Seock-Ah Im,Rina Hui,Toshimi Takano,Fabrice André,Hiroyuki Yasojima,Zhenzhen Liu,Yu Ding,Liyi Jia,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia, MD, MPH
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH,Paul V. Plourde,David J. Portman,Senthil Damodaran
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
ByHope S. Rugo, MD,Nadia Harbeck, MD, PhD,Priya Rastogi, MD,Joyce O’Shaughnessy, MD,Frances Boyle,Javier Cortés, MD,Matthew P. Goetz, MD,Erika P. Hamilton, MD,Chiun-Sheng Huang,Elżbieta Senkus,Alexey Tryakin,Patrick Neven, MD, PhD,Jens Huober, MD,Ran Wei,Valérie André,Maria Munoz,Belen San Antonio,Ashwin Shahir,Miguel Martin, MD, PhD,Stephen Johnston
In this interview we discuss the results of the CLEOPATRA trial, which studied the effect of adding pertuzumab to docetaxel and trastuzumab on HER2-positive metastatic breast cancer.
Advertisement
Latest Updated Articles
Javier Cortés, MD, on the CLEOPATRA TrialPublished: October 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
2
ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors
3
Cevostamab Combo Shows Enduring Responses in R/R Multiple Myeloma
4
Toripalimab Consolidation Improves Survival in Limited-Stage SCLC
5
